[HTML][HTML] Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

DB Johnson, MV Estrada, R Salgado… - Nature …, 2016 - nature.com
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, AE Vilgelm
Nature communications, 2016nature.com
Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma
patients. Since most patients do not respond, predictive biomarkers to guide treatment
selection are needed. We hypothesize that MHC-I/II expression is required for tumour
antigen presentation and may predict anti-PD-1 therapy response. In this study, across 60
melanoma cell lines, we find bimodal expression patterns of MHC-II, while MHC-I
expression was ubiquitous. A unique subset of melanomas are capable of expressing MHC …
Abstract
Anti-PD-1 therapy yields objective clinical responses in 30–40% of advanced melanoma patients. Since most patients do not respond, predictive biomarkers to guide treatment selection are needed. We hypothesize that MHC-I/II expression is required for tumour antigen presentation and may predict anti-PD-1 therapy response. In this study, across 60 melanoma cell lines, we find bimodal expression patterns of MHC-II, while MHC-I expression was ubiquitous. A unique subset of melanomas are capable of expressing MHC-II under basal or IFNγ-stimulated conditions. Using pathway analysis, we show that MHC-II(+) cell lines demonstrate signatures of ‘PD-1 signalling’, ‘allograft rejection’ and ‘T-cell receptor signalling’, among others. In two independent cohorts of anti-PD-1-treated melanoma patients, MHC-II positivity on tumour cells is associated with therapeutic response, progression-free and overall survival, as well as CD4+ and CD8+ tumour infiltrate. MHC-II+ tumours can be identified by melanoma-specific immunohistochemistry using commercially available antibodies for HLA-DR to improve anti-PD-1 patient selection.
nature.com